Get the app Watchlists Portfolios Alerts Sign in Get started

Menu

Raphael Pharmaceutical Inc. RAPH

Full chart Compare

Set alert

1.51 USD 0.00 (+0.00%)

At closeNov 2, 2026, 4:00 PM EST

1.51 Day range 1.51

0.748 52-week range 1.51

YTD: +7.86%
1 year: +51.00%

News

11 months ago globenewswire.com Raphael Pharmaceutical Announces Filing of Provisional Patent Application for the Treatment of Neutrophil-Dominant Autoimmune Diseases, Including Rheumatoid Arthritis (RA) NEW YORK, Nov. 17, 2025 (GLOBE NEWSWIRE) -- Raphael Pharmaceutical Inc. (“Raphael Pharmaceutical” or the “Company”) (OTCQB: RAPH), a clinical-stage biotechnology company developing an innovative…
1 year ago globenewswire.com Raphael Pharmaceutical Announces Positive Proof-of-Concept Clinical Study Results for the Company's Cannabinoid-Based Formula for the Treatment of Rheumatoid Arthritis * Patients in Study Reported Lower Pain Levels, Better Sleep Quality, and Improved Wellbeing * Disease Activity Score Decreased by 19.2%, Reflecting a Shift in Disease Activity from High to Moderate…
2 years ago globenewswire.com Raphael Pharmaceutical Issues Letter to Shareholders Highlights Company's exclusive relationship with Rambam Health Care Campus, differentiated cannabinoid-based technology platform, promising lead product candidate for rheumatoid arthritis, recently…